OverviewSuggest Edit

Nordic Nanovector, a biopharmaceutical company, focuses on the development and commercialization of novel targeted therapeutics in hematology and oncology. Its lead clinical-stage product candidate is Betalutin, an antibody-radionuclide-conjugate, which is in Phase I/II clinical trial for the treatment of patients with non-hodgkin lymphoma, a life-threatening blood cancer. The Company has a collaboration agreement with AREVA Med and Paul Scherrer Institute to develop antibody-drug conjugates for treating leukaemias; and LegoChem Biosciences and Heidelberg Pharma to develop Antibody Radionuclide conjugates.

TypePublic
Founded2009
HQOslo, NO
Websitenordicnanovector.com

Latest Updates

Employees (est.) (Feb 2019)40
Share Price (Jul 2020)KR20.5
Cybersecurity ratingAMore

Key People/Management at Nordic Nanovector

Jean-Pierre Bizzari

Jean-Pierre Bizzari

Director
Rainer Boehm

Rainer Boehm

Director
Marco Renoldi

Marco Renoldi

COO
Joanna Horobin

Joanna Horobin

Director
Gisela Schwab

Gisela Schwab

Director
Jostein Dahle

Jostein Dahle

Chief Scientific Officer
Show more

Nordic Nanovector Office Locations

Nordic Nanovector has offices in Oslo, Zug and Shrewsbury
Oslo, NO (HQ)
168 Kjelsåsveien
Zug, CH
10 Grafenauweg
Shrewsbury, GB
1 Brassey Rd
Show all (3)

Nordic Nanovector Financials and Metrics

Nordic Nanovector Revenue

Market capitalization (13-Jul-2020)

1.4b

Closing stock price (13-Jul-2020)

20.5
Nordic Nanovector's current market capitalization is kr1.4 b.
Show all financial metrics

Nordic Nanovector Cybersecurity Score

Cybersecurity ratingPremium dataset

A

98/100

SecurityScorecard logo

Nordic Nanovector Online and Social Media Presence

Embed Graph

Nordic Nanovector News and Updates

Nordic Nanovector to Amend PARADIGME Trial Protocol to Expand Eligible Patient Population

OSLO, Norway, June 30, 2020 /PRNewswire/ -- Nordic Nanovector ASA (OSE: NANO) announces that it will amend the trial protocol for its PARADIGME trial to broaden the inclusion criteria and expand the pool of eligible patients with the aim of increasing the present rate of enrolment. This...

Nordic Nanovector to Present at Upcoming Jefferies Virtual Healthcare Conference and ABG Sundal Collier Virtual Oncology Seminar

OSLO, Norway, June 2, 2020 /PRNewswire/ -- Nordic Nanovector ASA (OSE: NANO) announces that members of its management team will present at Jefferies Virtual Healthcare Conference, taking place 2-4 June 2020. Nordic Nanovector will also present at ABG Sundal Collier Virtual Oncology...

Nordic Nanovector ASA: Results for the First Quarter 2020

OSLO, Norway, May 26, 2020 /PRNewswire/ -- Nordic Nanovector ASA (OSE: NANO) announces its results for the first quarter 2020. A presentation by Nordic Nanovector's senior management team will take place today via a webcast at 08:30 am CET. A link to the webcast and a presentation is...

Nordic Nanovector Announces New Date for Annual General Meeting

OSLO, Norway, April 8, 2020 /PRNewswire/ -- Nordic Nanovector ASA (OSE: NANO) today announces a new date for its Annual General Meeting (AGM) as a result of the impact of the ongoing COVID-19 pandemic. The AGM will now be held on 10 June at 10.00 CET 2020 (previous 30 April 2020). All...

Nordic Nanovector ASA Announces Proposed Board Change

OSLO, Norway, March 19, 2020 /PRNewswire/ -- Nordic Nanovector ASA (OSE: NANO) announces that its Nomination Committee has nominated Dr Karin Meyer, PhD for election as a Non-executive Director at the Company's Annual General Meeting. The company also notes that Gisela Schwab, MD, who has...

Nordic Nanovector ASA - Results for the Fourth Quarter and Full Year 2019

OSLO, Norway, Feb. 27, 2020 /PRNewswire/ -- Nordic Nanovector ASA (OSE: NANO) announces its results for the fourth quarter and full year 2019. A presentation by the company's senior management team will take place today in Oslo at 08:30 CET, see details below. Jan H. Egberts, MD, Chairman...
Show more

Nordic Nanovector Frequently Asked Questions

  • When was Nordic Nanovector founded?

    Nordic Nanovector was founded in 2009.

  • Who are Nordic Nanovector key executives?

    Nordic Nanovector's key executives are Jean-Pierre Bizzari, Rainer Boehm and Marco Renoldi.

  • How many employees does Nordic Nanovector have?

    Nordic Nanovector has 40 employees.

  • Who are Nordic Nanovector competitors?

    Competitors of Nordic Nanovector include Brii Biosciences, ViewPoint Therapeutics and Acousia Therapeutics.

  • Where is Nordic Nanovector headquarters?

    Nordic Nanovector headquarters is located at 168 Kjelsåsveien, Oslo.

  • Where are Nordic Nanovector offices?

    Nordic Nanovector has offices in Oslo, Zug and Shrewsbury.

  • How many offices does Nordic Nanovector have?

    Nordic Nanovector has 3 offices.